Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Chair, Specialised Rheumatology CRG

Will acceptance of rituximab treatment for IgG4-RD by NHS England make it easier to treat complicated patients with IgG4-RD in the future? Or do you see further problems emerging?